Cargando…
A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy.
We assess the feasibility of using the MTT assay as a measure of cell viability in chemosensitivity testing in ovarian malignancy. The assay utilises the conversion of the tetrazolium salt MTT to formazan by dehydrogenase enzymes in living cells. We show that the optical density of the formazan prod...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971830/ https://www.ncbi.nlm.nih.gov/pubmed/2386733 |
_version_ | 1782134994602295296 |
---|---|
author | Wilson, J. K. Sargent, J. M. Elgie, A. W. Hill, J. G. Taylor, C. G. |
author_facet | Wilson, J. K. Sargent, J. M. Elgie, A. W. Hill, J. G. Taylor, C. G. |
author_sort | Wilson, J. K. |
collection | PubMed |
description | We assess the feasibility of using the MTT assay as a measure of cell viability in chemosensitivity testing in ovarian malignancy. The assay utilises the conversion of the tetrazolium salt MTT to formazan by dehydrogenase enzymes in living cells. We show that the optical density of the formazan produced from MTT is directly proportional to the number of live cells tested. Optimum MTT conversion occurred after 4 h incubation and dimethyl sulphoxide was found to be the most suitable solvent for the formazan. Seventy-five samples of ascitic fluid and/or solid tumour were collected from 56 patients with FIGO stage III-IV ovarian adenocarcinoma. Malignant cell suspensions with a viability greater than 75% were prepared from 95% of ascitic fluid and 75% of biopsy samples by simple techniques. The effect of cytotoxic drugs was assessed in 91% of patients included in the study. Variation in drug effect between patients was evident following a 48 h incubation period and was reproducible. Overall platinum and anthraquinone analogues produced the greater effect but resistance did occur. Our results mirrored reported clinical response rates. Only one sample tested against chlorambucil showed any drug effect. As this assay produces results in a high percentage of tests and is rapid and simple it appears suitable for prospective clinical trials to correlate the in vitro results with in vivo response. |
format | Text |
id | pubmed-1971830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1990 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19718302009-09-10 A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Wilson, J. K. Sargent, J. M. Elgie, A. W. Hill, J. G. Taylor, C. G. Br J Cancer Research Article We assess the feasibility of using the MTT assay as a measure of cell viability in chemosensitivity testing in ovarian malignancy. The assay utilises the conversion of the tetrazolium salt MTT to formazan by dehydrogenase enzymes in living cells. We show that the optical density of the formazan produced from MTT is directly proportional to the number of live cells tested. Optimum MTT conversion occurred after 4 h incubation and dimethyl sulphoxide was found to be the most suitable solvent for the formazan. Seventy-five samples of ascitic fluid and/or solid tumour were collected from 56 patients with FIGO stage III-IV ovarian adenocarcinoma. Malignant cell suspensions with a viability greater than 75% were prepared from 95% of ascitic fluid and 75% of biopsy samples by simple techniques. The effect of cytotoxic drugs was assessed in 91% of patients included in the study. Variation in drug effect between patients was evident following a 48 h incubation period and was reproducible. Overall platinum and anthraquinone analogues produced the greater effect but resistance did occur. Our results mirrored reported clinical response rates. Only one sample tested against chlorambucil showed any drug effect. As this assay produces results in a high percentage of tests and is rapid and simple it appears suitable for prospective clinical trials to correlate the in vitro results with in vivo response. Nature Publishing Group 1990-08 /pmc/articles/PMC1971830/ /pubmed/2386733 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Wilson, J. K. Sargent, J. M. Elgie, A. W. Hill, J. G. Taylor, C. G. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title | A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title_full | A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title_fullStr | A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title_full_unstemmed | A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title_short | A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. |
title_sort | feasibility study of the mtt assay for chemosensitivity testing in ovarian malignancy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971830/ https://www.ncbi.nlm.nih.gov/pubmed/2386733 |
work_keys_str_mv | AT wilsonjk afeasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT sargentjm afeasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT elgieaw afeasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT hilljg afeasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT taylorcg afeasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT wilsonjk feasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT sargentjm feasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT elgieaw feasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT hilljg feasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy AT taylorcg feasibilitystudyofthemttassayforchemosensitivitytestinginovarianmalignancy |